TLDR for Investors: Emyria Limited (ASX: EMD) focused on delivering innovative treatments for mental health and neurological conditions, reported strong revenue growth in mental health programs, with a significant increase in clinical billings and service-related revenues.

Emyria opened the Empax Centre for mental health treatments and received approvals to commence MDMA-assisted therapy. Additionally, the company entered research agreements for PTSD programs and was selected for a key site in a PTSD trial.

Financially, Emyria saw strong revenue growth and received non-dilutive grant funding for its drug development programs.

The company is focused on enhancing mental health care, expanding nationally, and advancing its drug development initiatives. Emyria's goal is to continue expanding patient access to high-quality mental health care and innovative treatments.

Investors can expect continued growth and development in the mental health and drug development sectors. Questions from investors are welcomed for further information!